Skip to main content
    K

    Karyopharm Therapeutics Inc (KPTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.02
    -0.02 (-56.50%)

    Market Cap: $394,660

    Last updated: Nov 10, 2026 at 7:59 PM ET

    Karyopharm Therapeutics Inc (KPTI) Statistics

    Updated Nov 10, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Karyopharm Therapeutics (KPTI) has a market cap of $394,660 and an enterprise value of $96.71M. Its net debt of $96.31M equals 24403.54% of its market cap. Its share count is up 235.71% from a year earlier.

    Total Valuation

    Enterprise value is 24403.54% above the market cap, as debt exceeds cash.

    Market Cap$394,660
    Enterprise Value$96.71M
    Latest price (Nov 10, 2026)$0.02

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 31.45% in the quarter ended Jun 30, 2026 and grew 5888.59% a year over 2 years.

    Shares Outstanding28.94M
    Shares Change (YoY)+235.71%
    Shares Change (QoQ)+31.45%
    Share Count Growth (2Y CAGR)+5888.59%

    Price Statistics

    The stock is down 99.66% over 52 weeks and trades 97.92% below its 50-day average.

    Beta (1Y)1.07
    52-Week Change-99.66%
    1-Month Change-96.56%
    3-Month Change-99.14%
    6-Month Change-99.80%
    5-Year Change-99.19%
    10-Year Change-99.39%
    Total Return (3Y CAGR)-88.74%
    Total Return (5Y CAGR)-83.17%
    Max Drawdown (1Y)-99.84%
    Max Drawdown (3Y)-99.93%
    Sharpe Ratio (1Y)-2.22
    Correlation with SPY (1Y)0.05
    50-Day Average$0.96
    200-Day Average$5.81
    52-Week Range$0.02 to $10.99
    RSI (14 Days)28.0
    Average Volume (20 Days)24.12M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.79x current liabilities.

    Current Ratio0.79x
    Quick Ratio0.76x
    Interest Coverage-1.03x

    Returns and Efficiency

    Return on invested capital is 64.55% over the last 12 months, against a 5-year average of 78.82%.

    Return on Assets (ROA)-201.89%
    Return on Invested Capital (ROIC)64.55%
    ROA (5Y Average)-74.72%
    ROIC (5Y Average)78.82%
    Asset Turnover1.36x
    Inventory Turnover1.59x
    Receivables Turnover5.51x
    Cash Conversion Cycle-65 days

    Scores

    KPTI has an Altman Z-Score of -25.66, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-25.66
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $146.62M over the last 12 months is up 6.81% from the 12 months before.

    Revenue$146.62M
    Revenue Growth (YoY)+6.81%
    Gross Profit$140.59M
    Operating Income-$82.35M
    Pretax Income-$224.77M
    Net Income-$224.74M
    EBIT-$115.48M
    Reported EPS (TTM)-$9.61

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$54.98M
    Total Debt$151.29M
    Net Debt$96.31M
    Net Debt Per Share$3.33
    Working Capital-$27.86M
    Shareholder Equity-$330.17M
    Total Assets$111.32M
    Total Liabilities$441.49M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$65.35M
    FCF Per Share-$2.88
    Depreciation and Amortization$10.19M

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -56.17%, against a 5-year average of -74.08%.

    Gross Margin95.89%
    Operating Margin-56.17%
    Pretax Margin-153.30%
    Net Margin-153.28%
    EBIT Margin-78.76%
    Gross Margin (5Y Average)96.69%
    Operating Margin (5Y Average)-74.08%
    Net Margin (5Y Average)-89.84%

    Growth

    Revenue fell 2.39% a year over 3 years.

    Revenue Growth (3Y CAGR)-2.39%
    Revenue Growth (5Y CAGR)+6.21%

    Revenue and profit by year

    Dividends and Yields

    KPTI does not pay a dividend.

    Buyback Yield-11530.60%
    Shareholder Yield-11530.60%

    Stock Splits

    The last split was a 1-for-15 reverse split on Feb 26, 2025.

    Last Split DateFeb 26, 2025
    Split TypeReverse split
    Split Ratio1:15

    Peer Position

    Against 5 similar companies, KPTI has the 3rd highest ROIC.

    ROIC64.55% vs -61.86% median
    Revenue Growth (Trailing 4 Quarters, YoY)+6.81% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 8.75% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+8.75%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About KPTI

    What is KPTI's market cap?

    Karyopharm Therapeutics has a market cap of $394,660. Its enterprise value, which adds debt and subtracts cash, is $96.71M.

    How many shares of KPTI are outstanding?

    Karyopharm Therapeutics has 28.94M shares outstanding. The count is up 235.71% from a year earlier.

    Does KPTI pay a dividend?

    No. Karyopharm Therapeutics does not pay a dividend.

    How much debt does KPTI have?

    Karyopharm Therapeutics has $151.29M of total debt and $54.98M of cash and equivalents, a net debt position of $96.31M.